Brain derived neurotrophic factor and serotonin transporter binding as markers of clinical response to fluoxetine therapy in children with autism

Journal of Pediatric Neurology

Volumn 9, Issue 1, 2011, Pages 1-8

  Makkonen, Ismo ^a   Riikonen, Raili ^a   Kuikka, Jyrki T ^a   Kokki, Hannu ^a   Bressler, Joseph P ^b   Marshall, Cathleen ^c   Kaufmann, Walter E ^c  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescent; autism; BDNF; children; clinical outcome; fluoxetine; serotonin transporter; SPECT

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; FLUOXETINE; SEROMEX; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; AWARENESS; BLOOD LEVEL; CHILD; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DRUG DOSE INCREASE; FEMALE; FRONTAL CORTEX; HUMAN; INFANT DISEASE; INFANTILE AUTISM; INTERPERSONAL COMMUNICATION; MALE; MESENCEPHALON; PHOTON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; PROTEIN BINDING; SCHOOL CHILD; SOCIALIZATION; TREATMENT RESPONSE;

EID: 79951965393     PISSN: 13042580     EISSN: 18759041     Source Type: Journal    
DOI: 10.3233/JPN-2010-0446     Document Type: Article

References (31)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
2. R. Riikonen, Insulin-like growth factors. Neurobiological regulators of brain growth in autism? in: Autism: Current Theories and Evidence, A. Zimmerman, ed., Totowa, NJ: Humana Press, 2008, pp. 233-244.
3. A.M. Connolly, M. Chez, E.M. Streif et al., Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy, Biol Psychiatry 59 (2006), 354-363. (Pubitemid 43238361)
4. K. Hashimoto, Y. Iwata, K. Nakamura et al., Reduced serum levels of brain-derived neurotrophic factor in adult male patients with autism, Prog Neuropsychopharmacol Biol Psychiatry 30 (2006), 1529-1531. (Pubitemid 44634961)
5. D.K. Binder and H.E. Scharfman, Brain-derived neurotrophic factor, Growth Factors 22 (2004), 123-131. (Pubitemid 39377904)
6. C.A. Pardo and C.G. Eberhart, The neurobiology of autism, Brain Pathol 17 (2007), 434-447. (Pubitemid 47537607)
7. D.C. Chugani, O. Muzik, R. Rothermel et al., Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys, Ann Neurol 42 (1997), 666-669. (Pubitemid 27439032)
8. M.L. Bauman and T.L. Kemper, Neuroanatomic observations of the brain in autism: a review and future directions, Int J Dev Neurosci 23 (2005), 183-187. (Pubitemid 40313551)
9. I. Makkonen, R. Riikonen, H. Kokki, M.M. Airaksinen and J.T. Kuikka, Serotonin and dopamine transporter binding in children with autism determined by SPECT, Dev Med Child Neurol 50 (2008), 593-597.
10. G.R. DeLong, C.R. Ritch and S. Burch, Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement, Dev Med Child Neurol 44 (2002), 652-659. (Pubitemid 35230025)
11. E. Hollander, A. Phillips, W. Chaplin et al., A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism, Neuropsychopharmacology 30 (2005), 582-589. (Pubitemid 40271160)
12. C.J. McDougle, S.T. Naylor, D.J. Cohen, F.R. Volkmar, G.R. Heninger and L.H. Price, A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder, Arch Gen Psychiatry 53 (1996), 1001-1008.
13. B.H. King, E. Hollander, L. Sikich et al., STAART Psychopharmacology Network. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism, Arch Gen Psychiatry 66 (2009), 583-590.
14. E. Castrén, Neurotrophic effects of antidepressant drugs, Curr Opin Pharmacol 4 (2004), 58-64. (Pubitemid 38145839)
15. B. Rimland and S.M. Edelson, Autism Treatment Evaluation Checklist (ATEC), Autism Research Institute, 4182 Adams Avenue, San Diego CA 92116, 2000. Retrieved from http://www.autism.com/ind-atec-survey.asp. Accessed on October 19. 2010.
16. E. Castrén, V. Võikar and T. Rantamäki, Role of neurotrophic factors in depression, Curr Opin Pharmacol 7 (2007), 18-21.
17. Z.J. Huang, A. Kirkwood, T. Pizzorusso et al., BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex, Cell 98 (1999), 739-755. (Pubitemid 29446892)
18. T.C. Bethea and L. Sikich, Early pharmacological treatment of autism: a rationale for developmental treatment, Biol Psychiatry 61 (2007), 521-537. (Pubitemid 46185342)
19. S.J. Tsai, TrkB partial agonists: potential treatment strategy for epilepsy, mania, and autism, Med Hypotheses 66 (2006), 173-175.
20. L.A. Croen, P. Goines, D. Braunschweig et al., Brain-derived neurotrophic factor and autism: maternal and infant peripheral blood levels in the Early Markers for Autism (EMA) Study, Autism Res 1 (2008), 130-137.
21. K. Miyazaki, N. Narita, R. Sakuta et al., Serum neurotrophin concentrations in autism and mental retardation: a pilot study, Brain Dev 26 (2004), 292-295. (Pubitemid 38692430)
22. K. Nishimura, K. Nakamura, A. Anitha et al., Genetic analyses of the brain-derived neurotrophic factor (BDNF) gene in autism, Biochem Biophys Res Commun 356 (2007), 200-206. (Pubitemid 46413149)
23. R. Vanhala, L. Korhonen, M. Mikelsaar, D. Lindholm and R. Riikonen, Neurotrophic factors in cerebrospinal fluid and serum of patients with Rett syndrome, J Child Neurol 13 (1998), 429-433. (Pubitemid 28473473)
24. W.E. Kaufmann, M.V. Johnston and M.E. Blue, MeCP2 expression and function during brain development: implications for Rett syndrome's pathogenesis and clinical evolution, Brain Dev 27(Suppl 1) (2005), S77-S87. (Pubitemid 41501614)
25. B.B. Zeev, A. Bebbington, G. Ho et al., The common BDNF polymorphism may be a modifier of disease severity in Rett syndrome, Neurology 72 (2009), 1242-1247.
26. M. Castrén, K.E. Lampinen, R. Miettinen et al., BDNF regulates the expression of fragile X mental retardation protein mRNA in the hippocampus, Neurobiol Dis 11 (2002), 221-229. (Pubitemid 35435687)
27. V. Louhivuori, M. Arvio, P. Soronen, V. Oksanen, T. Paunio and M.L. Castrén, The Val66Met polymorphism in the BDNF gene is associated with epilepsy in fragile X syndrome, Epilepsy Res 85 (2009), 114-117.
28. K. Nakamura, Y. Sekine, Y. Ouchi et al., Brain serotonin and dopamine transporter bindings in adults with high-functioning autism, Arch Gen Psychiatry 67 (2010), 59-68.
29. M.P. Mattson, S. Maudsley and B. Martin, BDNF and 5HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders, Trends Neurosci 27 (2004), 589-594. (Pubitemid 39221394)
30. E.H. Cook and B.L. Leventhal, The serotonin system in autism, Curr Opin Pediatr 8 (1996), 348-354. (Pubitemid 26393877)
31. G.R. DeLong, L.A. Teague and M. McSwain Kamran, Effects of fluoxetine treatment in young children with idiopathic autism, Dev Med Child Neurol 40 (1998), 551-562. (Pubitemid 28401249)